WO2009044722A1 - Gene susceptible to disease associated with intervertebral disc degeneration and use thereof - Google Patents
Gene susceptible to disease associated with intervertebral disc degeneration and use thereof Download PDFInfo
- Publication number
- WO2009044722A1 WO2009044722A1 PCT/JP2008/067720 JP2008067720W WO2009044722A1 WO 2009044722 A1 WO2009044722 A1 WO 2009044722A1 JP 2008067720 W JP2008067720 W JP 2008067720W WO 2009044722 A1 WO2009044722 A1 WO 2009044722A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- intervertebral disc
- disc degeneration
- disease associated
- gene
- diagnostic method
- Prior art date
Links
- 206010061246 Intervertebral disc degeneration Diseases 0.000 title abstract 6
- 208000018180 degenerative disc disease Diseases 0.000 title abstract 6
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 3
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 abstract 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 abstract 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 101150035730 Mmp9 gene Proteins 0.000 abstract 1
- 101150033395 THBS2 gene Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 108010060887 thrombospondin 2 Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
It is intended to provide a diagnostic method for a disease associated with intervertebral disc degeneration (such as intervertebral disc degeneration or disk herniation) by genetic diagnosis or hemodiagnosis. According to the invention, a diagnostic method for genetic susceptibility to a disease associated with intervertebral disc degeneration of a test subject is provided. The diagnostic method is characterized by detecting one or more polymorphisms selected from the group consisting of polymorphisms which are present in thrombospondin-2 gene (THBS2 gene) and/or matrix metalloproteinase-9 gene (MMP9 gene) and have a higher frequency of one of the alleles in an arbitrary group of patients with a disease associated with intervertebral disc degeneration than in an arbitrary group of individuals without a disease associated with intervertebral disc degeneration in a specimen containing DNA collected from the test subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-257345 | 2007-10-01 | ||
JP2007257345 | 2007-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009044722A1 true WO2009044722A1 (en) | 2009-04-09 |
Family
ID=40526150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/067720 WO2009044722A1 (en) | 2007-10-01 | 2008-09-30 | Gene susceptible to disease associated with intervertebral disc degeneration and use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009044722A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105385776A (en) * | 2015-12-24 | 2016-03-09 | 叶伟亮 | Application of CCDC57 genes to diagnosis and treatment of intervertebral disc degenerative disease |
CN105483242A (en) * | 2015-12-24 | 2016-04-13 | 叶伟亮 | Molecular marker related to intervertebral disc degenerative disease |
CN105483272A (en) * | 2016-01-29 | 2016-04-13 | 北京泱深生物信息技术有限公司 | Molecular marker for diagnosing and treating intervertebral disc degeneration disease |
CN105603085A (en) * | 2016-01-29 | 2016-05-25 | 北京泱深生物信息技术有限公司 | Diagnosis and treatment target of degenerative disc disease |
-
2008
- 2008-09-30 WO PCT/JP2008/067720 patent/WO2009044722A1/en active Application Filing
Non-Patent Citations (10)
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105385776A (en) * | 2015-12-24 | 2016-03-09 | 叶伟亮 | Application of CCDC57 genes to diagnosis and treatment of intervertebral disc degenerative disease |
CN105483242A (en) * | 2015-12-24 | 2016-04-13 | 叶伟亮 | Molecular marker related to intervertebral disc degenerative disease |
CN105385776B (en) * | 2015-12-24 | 2018-10-26 | 叶伟亮 | Application of the CCDC57 genes in Degenerative disc disease diagnosing and treating |
CN105483242B (en) * | 2015-12-24 | 2019-02-22 | 北京致成生物医学科技有限公司 | A kind of molecular marked compound relevant to Degenerative disc disease |
CN105483272A (en) * | 2016-01-29 | 2016-04-13 | 北京泱深生物信息技术有限公司 | Molecular marker for diagnosing and treating intervertebral disc degeneration disease |
CN105603085A (en) * | 2016-01-29 | 2016-05-25 | 北京泱深生物信息技术有限公司 | Diagnosis and treatment target of degenerative disc disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Gut microbiota differs between Parkinson’s disease patients and healthy controls in Northeast China | |
Weidner et al. | Aging of blood can be tracked by DNA methylation changes at just three CpG sites | |
Ross et al. | Ataxin-2 repeat-length variation and neurodegeneration | |
Lesser et al. | Culture-dependent and culture-independent analyses reveal no prokaryotic community shifts or recovery of Serratia marcescens in Acropora palmata with white pox disease | |
WO2017152137A2 (en) | Microbial consortium and uses thereof | |
EP2824191A3 (en) | Means and methods for non-invasive diagnosis of chromosomal aneuploidy | |
WO2005082042A3 (en) | Therapeutic methods employing nitric oxide precursors | |
Ellis et al. | Genetic risk underlying psychiatric and cognitive symptoms in Huntington’s disease | |
Oliphant et al. | Drivers of human gut microbial community assembly: coadaptation, determinism and stochasticity | |
WO2011143659A3 (en) | Nucleic acid isolation methods | |
Jain et al. | Molecular genetic pathways in Parkinson's disease: a review | |
Zhang et al. | A controlled case study of the relationship between environmental risk factors and apoptotic gene polymorphism and lumbar disc herniation | |
WO2010011683A3 (en) | Methods for the cytological analysis of cervical cells | |
WO2005113834A3 (en) | Single label comparative hybridization | |
WO2008122670A3 (en) | Human diabetes susceptibility tnfrsf10b gene | |
Gellera et al. | ATAXIN2 CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling | |
Przybyl et al. | What, when and how to measure—peripheral biomarkers in therapy of Huntington’s disease | |
WO2009044722A1 (en) | Gene susceptible to disease associated with intervertebral disc degeneration and use thereof | |
WO2007044780A3 (en) | Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies | |
AU2010202926B2 (en) | Markers and methods relating to the assessment of Alzheimer's disease | |
Hameed et al. | Draft genome sequence reveals co-occurrence of multiple antimicrobial resistance and plant probiotic traits in rice root endophytic strain Burkholderia sp. LS-044 affiliated to Burkholderia cepacia complex | |
Cabantous et al. | Gene expression analysis reveals genes common to cerebral malaria and neurodegenerative disorders | |
Savinetti et al. | Human monocytes plasticity in neurodegeneration | |
CN101240320A (en) | Kit for detecting cardiovascular disease incidence inheritance risk | |
WO2007053752A3 (en) | Computerized systems and methods for assessment of genetic test results |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08835164 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08835164 Country of ref document: EP Kind code of ref document: A1 |